Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;23(12):909–914. doi: 10.1002/clc.4960231211

Effect of Heart Failure Program on Cardiovascular Drug Utilization and Dosage in Patients with Chronic Heart Failure

Tarik M Ramahi 1,✉, Marcella D Longo 1, Kate Rohlfs 1, Natalie Sheynberg 1
PMCID: PMC6655153  PMID: 11129677

Abstract

Background: Utilization and dosage of angiotensin‐converting enzyme (ACE) inhibitors in patients with chronic heart failure (CHF) remain low. Recent data suggest that care of patients with CHF in specialized heart failure programs is associated with improved clinical outcomes.

Hypothesis: Specialized heart failure care is associated with better utilization and higher dose of cardiovascular drugs.

Methods: Data from 133 patients with CHF referred to a heart failure program were analyzed. Mean functional class 3.1 ± 0.5, left ventricular ejection fraction 19 ± 8. Utilization and doses of cardiovascular drugs were examined at initial evaluation and at last visit, after an average period of 17 ± 14 months. Hospitalization and survival data were determined.

Results: Utilization of ACE inhibitors and angiotensin‐receptor blockers increased from 87 to 100% (p< 0.001). Average daily dose increased by 60%, from the equivalent of captopril 105 ± 78 mg to 167 ± 86 mg (p < 0.001). Utilization of the following drugs increased significantly: beta blockers (16–37%, p< 0.001), metolazone (10–23%, p = 0.007), spironolactone (l‐36%, p<0.001), amiodarone (7–15%, p=0.05), hydralazine (1–9%, p = 0.004), and nitrates (20–33%, p = 0.03). One‐year survival was 90%. The 3‐ and 6‐month hospitalization rates for heart failure were 4 and 7%, and for all cardiovascular causes they were 6 and 11%, respectively.

Conclusions: Care of patients with CHF in a specialized heart failure program was associated with significant increase in the utilization and doses of all beneficial cardiovascular drugs, especially ACE inhibitors. It was also associated with excellent clinical outcomes.

Keywords: heart failure, drug utilization and doses, angiotensin‐converting enzyme inhibitors

Full Text

The Full Text of this article is available as a PDF (653.7 KB).

References

  • 1. SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293–302 [DOI] [PubMed] [Google Scholar]
  • 2. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C: A comparison of enalapril with hydralazine‐isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–310 [DOI] [PubMed] [Google Scholar]
  • 3. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B: Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547–1552 [DOI] [PubMed] [Google Scholar]
  • 4. American Heart Association : 1997. Heart and Stroke statistics update.
  • 5. American Heart Association : 1988. Heart Facts. American Heart Association, Dallas, Texas: 1988 [Google Scholar]
  • 6. O'Connell JB, Bristow MR: Economic impact of heart failure in the United States: Time for different approach. J Heart Lung Transplant 1994; 13: 107–112 [PubMed] [Google Scholar]
  • 7. Konstam MA, Dracup K, Baker DW: Heart failure: Evaluation and care of patients with left‐ventricular systolic dysfunction. Rockville, Md.: Agency for Health Care Policy and Research; Clinical Practice Guideline No. 11, 1994. [Google Scholar]
  • 8. Parmely WW: Cost‐effective cardiology: Cost‐effective management of heart failure. Clin Cardiol 1996; 19: 240–242 [DOI] [PubMed] [Google Scholar]
  • 9. The CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–1435 [DOI] [PubMed] [Google Scholar]
  • 10. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials : Overview of randomized trials of angiotensin‐converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J Am Med Assoc 1995; 273: 1450–1456 [PubMed] [Google Scholar]
  • 11. Captopril Multicenter Research Group : A placebo‐controlled trial of captopril in refractory congestive heart failure. J Am Coll Cardiol 1983; 4: 755–763 [DOI] [PubMed] [Google Scholar]
  • 12. Sharpe DN, Murphy J, Coxon R, Hannan S: Enalapril in patients with chronic congestive heart failure: A placebo‐controlled, randomized, double‐blind study. Circulation 1984; 70: 271–278 [DOI] [PubMed] [Google Scholar]
  • 13. Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B: Clinical consequences of angiotensin‐converting enzyme inhibitor withdrawal in chronic heart failure: A double‐blind, placebo‐controlled study of quinapril. The Quinapril Heart Failure Trial Investigators. J Am Coll Cardiol 1993; 22: 1557–1563 [DOI] [PubMed] [Google Scholar]
  • 14. SOLVD Investigators : Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–691 [DOI] [PubMed] [Google Scholar]
  • 15. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–677 [DOI] [PubMed] [Google Scholar]
  • 16. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators : Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1992; 342: 821–828 [PubMed] [Google Scholar]
  • 17. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico : GISSI‐3: Effect of lisinopril and transdermal glyceryl trinitrate singly and together on 6‐week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–1122 [PubMed] [Google Scholar]
  • 18. Packer M, Poole‐Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, Rydén L, Thygesen K, Uretsky BF, on behalf of the ATLAS Study Group : Comparative effects of low and high doses of the angiotensin‐converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312–2318 [DOI] [PubMed] [Google Scholar]
  • 19. Packer M: Do angiotensin‐converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol 1996; 28: 1323–1327 [DOI] [PubMed] [Google Scholar]
  • 20. Luzier AB, Forrest A, Adelman M, Hawari FI, Schentag JJ, Izzo JL: Impact of angiotensin‐converting enzyme inhibitors underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998; 82: 465–469 [DOI] [PubMed] [Google Scholar]
  • 21. Philben EF, Andreou C, Rocco T, Lunch LJ, Baker SL: Patterns of angiotensin‐converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996; 77: 832–838 [DOI] [PubMed] [Google Scholar]
  • 22. Smith NL, Psaty BM, Pitt B, Garg R, Gottdiener JS, Heckbert SR: Temporal patterns in the medical treatment of congestive heart failure with angiotensin‐converting enzyme inhibitors in older adults, 1989 through 1995. Arch Intern Med 1998; 158: 1074–1080 [DOI] [PubMed] [Google Scholar]
  • 23. Havranek EP, Graham GW, Pan Z, Lowes B: Process and outcome of outpatient management of heart failure: A comparison of cardiologists and primary care providers. Am J Managed Care 1996; 2: 783–789 [Google Scholar]
  • 24. Hanumanthu S, Butler J, Chomsky D, Davis S, Wilson JR: Effect of heart failure program on hospitalization frequency and exercise tolerance. Circulation 1997; 96: 2842–2848 [DOI] [PubMed] [Google Scholar]
  • 25. Riegger GAJ: Effects of quinapril on exercise tolerance testing in patients with mild to moderate congestive heart failure. Eur Heart J 1991; 12: 705–711 [DOI] [PubMed] [Google Scholar]
  • 26. Sharpe DN, Douglas JE, Coxon RJ, Long B: Low dose captopril in chronic heart failure: Acute haemodynamic effects and long‐term treatment. Lancet 1980; 2: 1154–1157 [DOI] [PubMed] [Google Scholar]
  • 27. Uretsky BF, Shaver JA, Liang C‐S, Amin D, Shah PK, Levine TB, Walinsky P, LeJemtel T, Linnemeier T, Rush JE, Langendorfer A, Snapinn S: Modulation of hemodynamic effects with converting enzyme inhibitor: Acute hemodynamic dose‐response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observation on long‐term clinical, functional and biochemical responses. Am Heart J 1988; 116: 480–488 [DOI] [PubMed] [Google Scholar]
  • 28. Pacher R, Globits S, Bergler‐Klein J, Teufelsbauer H, Wutte M, Baumgartner W, Ogris E, Glogar D: Clinical and neurohumoral response of patients with severe congestive heart failure treated with two different captopril dosages. Eur Heart J 1993; 14: 273–278 [DOI] [PubMed] [Google Scholar]
  • 29. Lampert MB, Lang RM: Underdosing and underutilization of ACE inhibitors in CHE Prim Cardiol 1995; 21: 7–11 [Google Scholar]
  • 30. Philbin EF: Current community practices in heart failure: Underdosing and underutilization of angiotensin‐converting enzyme inhibitors (abstr). J Am Coll Cardiol 1997; 29: 325A [Google Scholar]
  • 31. Chin MH, Friedmann PD, Cassel CK, Lang RM: Differences in generalist and specialist physician's knowledge regarding use of ace inhibitors for congestive heart failure (abstr). J Am Coll Cardiol 1997; 29: 324A [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Ghali JK, Kumar S, Sarkar IC, Horswell R, Livaudais G, Murgo JP, Giles T: Factors influencing underutilization of angiotensin converting enzyme inhibitors in inpatients with heart failure (abstr). J Am Coll Cardiol 1997; 29: 324A [Google Scholar]
  • 33. Aaronson KD, Glied SA, Sisk JE: Treatment of heart failure in the national ambulatory medical care survey (NAMCS) (abstr). J Am Coll Cardiol 1997; 29: 168A 8996310 [Google Scholar]
  • 34. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–1355 [DOI] [PubMed] [Google Scholar]
  • 35. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI, on behalf of ELITE Study investigators : Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997; 349: 747–752 [DOI] [PubMed] [Google Scholar]
  • 36. Packer M, Colucci WS, Sackner‐Bernstein JD, Liang C‐S, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH, for the PRECISE Study Group : Double‐blind, placebo‐controlled study of effects of carvedilol in patients with moderate to severe heart failure: The Prospective Randomized Evaluation of Carvedilol in Symptoms and Exercise. Circulation 1996; 94: 2793–2799 [DOI] [PubMed] [Google Scholar]
  • 37. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner‐Bernstein JD, Young ST, Holcslaw TL, Lukas MA, for the US Carvedilol Heart Study Group : Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800–2806 [DOI] [PubMed] [Google Scholar]
  • 38. Bristow MR, Gilbert EM, Abraham WT: Carvedilol produces dose‐related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807–2816 [DOI] [PubMed] [Google Scholar]
  • 39. Lechat P, Packer M, Chalon S, Cucherate M, Arab T, Boissel J‐P: Clinical effects of b̃‐andrenergic blockade in chronic heart failure. Circulation 1998; 98: 1184–1191 [DOI] [PubMed] [Google Scholar]
  • 40. CIBIS‐II Investigators and Committees : The Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): A randomized trial. Lancet 1999; 353: 9–13 [PubMed] [Google Scholar]
  • 41. MERIT‐HF Study Group : Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT‐HF). Lancet 1999; 353: 2001–2007 [PubMed] [Google Scholar]
  • 42. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for die Randomized Aldactone Evaluation Study Investigators : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999: 341: 709–717 [DOI] [PubMed] [Google Scholar]
  • 43. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R: Randomised trial of low‐dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493–498 [DOI] [PubMed] [Google Scholar]
  • 44. Massie BM, Fisher SG, Deedwania PC, Singh BN, Fletcher RD, Singh SN: Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 1996; 93: 2128–2134 [DOI] [PubMed] [Google Scholar]
  • 45. Packer M, Cohn JN, on behalf of the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure : Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83 (suppl 2A): 24A [PubMed] [Google Scholar]
  • 46. Rich MW, Beckman V, Wittenberg C, Leven CL, Freedland KE, Carney RM: A multidisciplinary intervention to prevent the read‐mission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190–1195 [DOI] [PubMed] [Google Scholar]
  • 47. Smith LE, Fabri SA, Heywood JT: The cost effectiveness of managing patients in cardiomyopathy clinic (abstr). Circulation 1996; 94 (suppl I): I–169 [Google Scholar]
  • 48. Philbin EF, DiSalvo TG: Hospital outcomes in heart failure are superior at a large tertiary care teaching institution (abstr). J Am Coll Cardiol 1997; 29: 168A 8996310 [Google Scholar]
  • 49. Abraham WT, Bristow MR: Specialized centers for heart failure management. J Am Coll Cardiol 1997; 96: 2755–2757 [DOI] [PubMed] [Google Scholar]
  • 50. Stevenson WG, Stevenson LW, Middlekauff HR, Fonarow GC, Hamilton MA, Woo MA, Saxon LA, Natterson PD, Steimle A, Walden JA, Tillisch JH: Improving survival for patients with advanced heart failure: A study of 737 consecutive patients. J Am Coll Cardiol 1995; 26: 1417–1423 [DOI] [PubMed] [Google Scholar]
  • 51. Rickenbacher PR, Trindade PT, Haywood GA, Vagelos RH, Schroeder JS, Willson K, Prikazsky L, Fowler MB: Transplant candidates with severe left ventricular dysfunction managed with medical treatment: Characteristics and survival. J Am Coll Cardiol 1996; 27: 1192–1197 [DOI] [PubMed] [Google Scholar]
  • 52. Hosenpud JD, Bennett L, Keck BM, Fiol B, Boucek MM, Novick RJ: The registry of the International Society of Heart and Lung Transplantation: Sixteenth official report—1999. J Heart Lung Transplant 1999; 18: 611–626 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES